Valuation: Matinas BioPharma Holdings, Inc.

Market Cap 2.48M 2.18M 2.06M 1.87M 3.51M 238M 3.53M 24.63M 9.51M 121M 9.3M 9.1M 390M P/E 2024
-0.1x
P/E 2025 -0.29x
Enterprise Value -167K -147K -139K -126K -236K -16.01M -238K -1.66M -640K -8.17M -626K -613K -26.26M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
76.25%
Yield 2024 *
-
Yield 2025 -
1 day+5.42%
1 week+5.15%
Current month-14.69%
1 month-15.67%
3 months-73.74%
6 months-69.92%
Current year-71.22%
1 week 2.31
Extreme 2.312999
2.7
1 month 2.26
Extreme 2.257649
3.07
Current year 2.26
Extreme 2.257649
13.6
1 year 2.26
Extreme 2.257649
29.85
3 years 2.26
Extreme 2.257649
667.5
5 years 2.26
Extreme 2.257649
1,087.5
10 years 2.26
Extreme 2.257649
2,992.5
Manager TitleAgeSince
Chief Executive Officer 52 15/03/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 52 13/03/2025
Director/Board Member 61 04/02/2025
Director/Board Member 55 10/03/2025
Date Insider Type Main position Quantity % Market Cap. Importance
30/04/25 Free

Chief Executive Officer

70,100 1.3780%
30/04/25 Free

Director

11,600 0.2280%
30/04/25 Free

Director

11,600 0.2280%
Change 5-day change 1-year change 3-year change Capi.($)
+5.42%+5.15%-91.12%-97.44% 2.35M
-0.37%+1.12%+57.21%+84.56% 72.26B
-0.07%-3.08%+37.74%+84.21% 60.24B
+0.75%+6.06%+36.71%+19.87% 27.73B
-0.14%-1.94%-14.13%+354.32% 25.73B
+0.57%+3.14%+1.02%-3.92% 24.75B
+1.10%+1.86%+25.07%-8.51% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
+0.36%+0.02%+49.51%+163.05% 14.41B
-2.53%-1.39%-6.38%+469.36% 14.23B
Average +0.34%-0.15%+24.59%+138.87% 27.52B
Weighted average by Cap. -0.12%-1.05%+38.13%+125.29%

Financials

2024 2025
Net sales - -
Net income -24.25M -21.33M -20.17M -18.3M -34.36M -2.33B -34.55M -241M -93.09M -1.19B -91.04M -89.07M -3.82B -10.34M -9.1M -8.6M -7.81M -14.66M -993M -14.74M -103M -39.71M -507M -38.84M -38M -1.63B
Net Debt -4.39M -3.86M -3.65M -3.31M -6.22M -421M -6.26M -43.63M -16.85M -215M -16.48M -16.12M -691M -2.64M -2.33M -2.2M -2M -3.75M -254M -3.77M -26.28M -10.15M -130M -9.93M -9.71M -416M
Logo Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Employees
2
Date Price Change Volume
28/09/26 US$2.530 +5.42% 116,593
25/09/26 US$2.400 -10.11% 52,013
24/09/26 US$2.670 +1.71% 15,746
23/09/26 US$2.625 -1.13% 28,145
22/09/26 US$2.655 +1.78% 13,722

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MTNB Stock